{"id":"shr-8068-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SHR-8068 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the interaction between PD-L1 and its receptors (PD-1 and B7-1). This blockade releases the brakes on T-cell mediated anti-tumor immunity, allowing cytotoxic T lymphocytes to recognize and eliminate cancer cells more effectively.","oneSentence":"SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:27.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07071714","phase":"PHASE2","title":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-22","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT07028281","phase":"PHASE2","title":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-08","conditions":"Malignant Solid Tumors","enrollment":120},{"nctId":"NCT07229625","phase":"PHASE3","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-01-21","conditions":"Advanced Biliary Tract Cancer","enrollment":604},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT06703177","phase":"PHASE1, PHASE2","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-18","conditions":"Advanced Solid Tumors","enrollment":876},{"nctId":"NCT06247956","phase":"PHASE2","title":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-11","conditions":"Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma","enrollment":153},{"nctId":"NCT06859775","phase":"PHASE1, PHASE2","title":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-25","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":100},{"nctId":"NCT06618664","phase":"PHASE3","title":"Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-10-28","conditions":"Advanced Hepatocellular Carcinoma","enrollment":590},{"nctId":"NCT06754930","phase":"PHASE1, PHASE2","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-18","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":400},{"nctId":"NCT06844474","phase":"PHASE2","title":"A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-07","conditions":"NSCLC","enrollment":300},{"nctId":"NCT06639347","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-04","conditions":"Advanced Urothelial Carcinoma","enrollment":90},{"nctId":"NCT06589778","phase":"PHASE1, PHASE2","title":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-09-27","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT05416775","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-08-15","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anti-CTLA4 monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"SHR-8068 injection","genericName":"SHR-8068 injection","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}